Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Livdelzi
Pharma
With trial success, Gilead paves way for broader use of Livdelzi
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint, showing its ability to help more patients with primary biliary cholangitis.
Kevin Dunleavy
Jun 2, 2026 10:55am
Gilead fashions new primary biliary cholangitis campaign
Sep 10, 2025 7:00am
Ipsen touts early launch results for liver disease drug Iqirvo
Apr 17, 2025 8:47am
Gilead charts course for long-acting PrEP launch
Feb 12, 2025 9:12am
Key drugs from Merck, Bayer and Gilead win EMA backing
Dec 13, 2024 10:33am
